Compare Adaptive Biotechnologies Corp (ADPT) vs HP Inc (HPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs HP Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while HP Inc trades at $23.82 (market cap $21.00B). The key difference: HP Inc is far larger — about 6.3× Adaptive Biotechnologies Corp's market cap, and HP Inc pays a 5.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HPQ | |
|---|---|---|
Market Cap | $3.33B | $21.00B |
Sector | Health | Technology |
52-Week High | $22.37 | $29.35 |
52-Week Low | $10.24 | $18.20 |
Enterprise Value | $3.19B | $28.16B |
Dividend Yield | — | 5.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HPQ trades at $22.96, up 4.7% today, with strong earnings momentum as it has beaten EPS estimates for three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 8.37 and P/S of 0.37, while technical indicators signal bearish momentum despite oversold RSI conditions. Recent developments include strategic AI partnerships with OpenAI and Ferrari, positioning the company for potential growth in the AI PC market.
The outlook remains cautiously optimistic with analyst consensus at $22.00, slightly below current price. Key opportunities include AI PC adoption and margin expansion, while risks involve competitive pressures and declining profit margins. Institutional sentiment leans neutral with 55% hold ratings, suggesting balanced risk-reward for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
